Plus, news about Jeyou and Invidior:
🪓 Y-mAbs axes Phase 1 radiopharma trial: The biotech canned the study in patients with non-Hodgkin lymphoma due to “recruitment challenges,” according to an
ACIP is being broken up. No it’s not. On Thursday afternoon, an outspoken member of the CDC’s Advisory Committee on Immunization Practices claimed that the
In San Francisco a few weeks ago, I caught up with Nworah Ayogu, partner at Thrive Capital. Thrive had recently announced that it raised a
The US FDA has approved a fourth product via its new National Priority Voucher Programme — a 7.2 mg dose of Novo Nordisk’s weight loss
The FDA approved a high-dose version of Novo Nordisk’s blockbuster weight loss injection Wegovy, giving its go-ahead about two months faster than normal thanks to
Verily has raised $300 million in new, outside funding that ends parent company Alphabet’s controlling position in the healthcare innovation company, Endpoints News has learned
Plus, news about Jeyou and Invidior:
🪓 Y-mAbs axes Phase 1 radiopharma trial: The biotech canned the study in patients with non-Hodgkin lymphoma due to “recruitment challenges,” according to an